Vaccines for established cancer: Overcoming the challenges posed by immune evasion

Nature Reviews Cancer

Volumn 16, Issue 4, 2016, Pages 219-233

  Van Der Burg, Sjoerd H ^a   Arens, Ramon ^a   Ossendorp, Ferry ^a   Van Hall, Thorbald ^a   Melief, Cornelis J M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISA Pharmaceuticals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DOWN REGULATION; HUMAN; IMMUNE EVASION; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; TUMOR ESCAPE;

CANCER VACCINES; HUMANS; T-LYMPHOCYTES; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84960372950     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc.2016.16     Document Type: Review

References (244)

1. Melief C. J, & van der Burg S. H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer. 8, 351-360 (2008).
2. Melief C. J, van Hall T, Arens R, Ossendorp F, & van der Burg S. H. Therapeutic cancer vaccines. J. Clin. Invest. 125, 3401-3412 (2015).
3. Talebian Yazdi M, Keene K. R, Hiemstra P. S, & van der Burg S. H. Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Rev. Vaccines. 13, 87-116 (2014).
4. Melero I, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat. Rev. Clin. Oncol. 11, 509-524 (2014).
5. Kraynyak K. A, Bodles-Brakhop A, & Bagarazzi M. Tapping the potential of DNA delivery with electroporation for cancer immunotherapy. Curr. Top. Microbiol. Immunol. http://dx.doi.org/.10.1007/82-2015-431 (2015).
6. Sahin U, Kariko K, & Tureci O. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug. Discov. 13, 759-780 (2014).
7. Butterfield L. H. Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front. Immunol. 4, 454 (2013).
8. Lichty B. D, Breitbach C. J, Stojdl D. F, & Bell J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer. 14, 559-567 (2014).
9. Sawada Y, et al. Programmed death 1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 46, 28-36 (2015).
10. Binder D. C, et al. Antigen-specific bacterial vaccine combined with anti PD L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol. Res. 1, 123-133 (2013).
11. Schreiber R. D, Old L. J, & Smyth M. J. Cancer immunoediting: integrating immunity?s roles in cancer suppression, and promotion. Science. 331, 1565-1570 (2011).
12. Finn O. J. Vaccines for cancer prevention: a practical, and feasible approach to the cancer epidemic. Cancer Immunol. Res. 2, 708-713 (2014).
13. Gubin M. M, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 515, 577-581 (2014).
14. Engelhard V. H, Bullock T. N, Colella T. A, Sheasley S. L, & Mullins D. W. Antigens derived from melanocyte differentiation proteins: self-Tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188, 136-146 (2002).
15. Bos R, et al. Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T cell repertoire. Cancer Res. 65, 6443-6449 (2005).
16. Pedersen S. R, Sorensen M. R, Buus S, Christensen J. P, & Thomsen A. R. Comparison of vaccine-induced effector CD8 T cell responses directed against self-, and non-self-Tumor antigens: implications for cancer immunotherapy. J. Immunol. 191, 3955-3967 (2013).
17. Alvarez I, et al. Central T cell tolerance: identification of tissue-restricted autoantigens in the thymus HLA DR peptidome. J. Autoimmun. 60, 12-19 (2015).
18. Yamano T, et al. Thymic B cells are licensed to present self antigens for central T cell tolerance induction. Immunity. 42, 1048-1061 (2015).
19. Prehn R. T, & Main J. M. Immunity to methylcholanthrene-induced sarcomas. J. Natl Cancer Inst. 18, 769-778 (1957).
20. Kripke M. L, & Fisher M. S. Immunologic parameters of ultraviolet carcinogenesis. J. Natl Cancer Inst. 57, 211-215 (1976).
21. Klein E, & Klein G. Antigenic properties of lymphomas induced by the Moloney agent. J. Natl Cancer Inst. 32, 547-568 (1964).
22. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313, 1960-1964 (2006).
23. Donnem T, et al. Stromal CD8+ T cell density-A promising supplement to TNM staging in non-small cell lung cancer. Clin. Cancer Res. 21, 2635-2643 (2015).
24. Ladanyi A. Prognostic, and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 28, 490-500 (2015).
25. Piersma S. J, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 67, 354-361 (2007).
26. Cariani E, et al. Immunological, and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma. PLoS ONE 7, e32493 (2012).
27. Van der Burg S. H, Arens R, & Melief C. J. Immunotherapy for persistent viral infections, and associated disease. Trends Immunol. 32, 97-103 (2011).
28. Rizvi N. A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD 1 blockade in non-small cell lung cancer. Science. 348, 124-128 (2015).
29. Snyder A, et al. Genetic basis for clinical response to CTLA 4 blockade in melanoma. N. Engl. J. Med. 371, 2189-2199 (2014).
30. Garon E. B, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018-2028 (2015).
31. Larkin J, et al. Combined nivolumab, and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
32. Le D. T, et al. PD 1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509-2520 (2015).
33. Kreiter S, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 520, 692-696 (2015).
34. Van Rooij N, et al. Tumor exome analysis reveals neoantigen-specific T cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
35. Linnemann C, et al. High-Throughput epitope discovery reveals frequent recognition of neo-Antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
36. Robbins P. F, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747-752 (2013).
37. Ruiter D. J, Bhan A. K, Harrist T. J, Sober A. J, & Mihm M. C. Jr. Major histocompatibility antigens, and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations, and malignant melanoma. J. Immunol. 129, 2808-2815 (1982).
38. Natali P. G, et al. Heterogeneity in the expression of HLA, and tumor-Associated antigens by surgically removed, and cultured breast carcinoma cells. Cancer Res. 43, 660-668 (1983).
39. Marincola F. M, Jaffee E. M, Hicklin D. J, & Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms, and functional significance. Adv. Immunol. 74, 181-273 (2000).
40. Garrido F, Cabrera T, & Aptsiauri N. Hard, and soft lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer. 127, 249-256 (2010).
41. Van Esch E. M, et al. Alterations in classical, and nonclassical HLA expression in recurrent, and progressive HPV-induced usual vulvar intraepithelial neoplasia, and implications for immunotherapy. Int. J. Cancer. 135, 830-842 (2014).
42. Vermeulen C. F, et al. Frequent HLA class I loss is an early event in cervical carcinogenesis. Hum. Immunol. 66, 1167-1173 (2005).
43. Seliger B, et al. Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur. J. Immunol. 28, 122-133 (1998).
44. Vertuani S, et al. HER 2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA A2 transgenic mice. Cancer Immunol. Immunother. 58, 653-664 (2009).
45. Concha-Benavente F, Srivastava R. M, Ferrone S, & Ferris R. L. EGFR-mediated tumor immunoescape: the imbalance between phosphorylated STAT1, and phosphorylated STAT3. Oncoimmunology 2, e27215 (2013).
46. Georgopoulos N. T, Proffitt J. L, & Blair G. E. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1, and LMP2 genes by the human papillomavirus (HPV) type 6b, 16, and 18 E7 oncoproteins. Oncogene. 19, 4930-4935 (2000).
47. Charni S, et al. Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. J. Immunol. 185, 3498-3503 (2010).
48. Bartoszewski R, et al. The unfolded protein response (UPR)-Activated transcription factor X box-binding protein 1 (XBP1) induces microRNA 346 expression that targets the human antigen peptide transporter 1 (TAP1) mRNA, and governs immune regulatory genes. J. Biol. Chem. 286, 41862-41870 (2011).
49. Setiadi A. F, et al. Epigenetic enhancement of antigen processing, and presentation promotes immune recognition of tumors. Cancer Res. 68, 9601-9607 (2008).
50. Khan A. N, Gregorie C. J, & Tomasi T. B. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes, and MHC class I antigen presentation by melanoma cells. Cancer Immunol. Immunother. 57, 647-654 (2008).
51. Fruci D, et al. Altered expression of endoplasmic reticulum aminopeptidases ERAP1, and ERAP2 in transformed non-lymphoid human tissues. J. Cell. Physiol. 216, 742-749 (2008).
52. Koopman L. A, Corver W. E, van der Slik A. R, Giphart M. J, & Fleuren G. J. Multiple genetic alterations cause frequent, and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 191, 961-976 (2000).
53. Del Campo A. B, et al. Immune escape of cancer cells with beta2 microglobulin loss over the course of metastatic melanoma. Int. J. Cancer. 134, 102-113 (2014).
54. Cabrera T, et al. HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. Cancer Immunol. Immunother. 56, 709-717 (2007).
55. Carretero R, et al. Analysis of HLA class I expression in progressing, and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics. 60, 439-447 (2008).
56. Seliger B. Novel insights into the molecular mechanisms of HLA class I abnormalities. Cancer Immunol. Immunother. 61, 249-254 (2012).
57. Saric T, et al. An IFNγ-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I presented peptides. Nat. Immunol. 3, 1169-1176 (2002).
58. Lampen M. H, & van Hall T. Strategies to counteract MHC I defects in tumors. Curr. Opin. Immunol. 23, 293-298 (2011).
59. Van Hall T, et al. Selective cytotoxic T lymphocyte targeting of tumor immune escape variants. Nat. Med. 12, 417-424 (2006).
60. Seidel U. J, Oliveira C. C, Lampen M. H, & Hall T. A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens. Cancer Immunol. Immunother. 61, 119-125 (2012).
61. Oliveira C. C, et al. Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires. Eur. J. Immunol. 41, 3114-3124 (2011).
62. Shastri N, Nagarajan N, Lind K. C, & Kanaseki T. Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum. Curr. Opin. Immunol. 26, 123-127 (2014).
63. Oliveira C. C, et al. New role of signal peptide peptidase to liberate C terminal peptides for MHC class I presentation. J. Immunol. 191, 4020-4028 (2013).
64. Oliveira C. C, et al. Dominant contribution of the proteasome, and metalloproteinases to TAP-independent MHC I peptide repertoire. Mol. Immunol. 62, 129-136 (2014).
65. Nagarajan N. A, Gonzalez F, & Shastri N. Nonclassical MHC class Ib restricted cytotoxic T cells monitor antigen processing in the endoplasmic reticulum. Nat. Immunol. 13, 579-586 (2012).
66. Chambers B, et al. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination. Cancer Res. 67, 8450-8455 (2007).
67. Lampen M. H, et al. CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population. J. Immunol. 185, 6508-6517 (2010).
68. Durgeau A, et al. Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL. J. Immunol. 187, 5532-5539 (2011).
69. Noman M. Z, et al. Hypoxia-inducible miR 210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res. 72, 4629-4641 (2012).
70. Noman M. Z, et al. PD L1 is a novel direct target of HIF 1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781-790 (2014).
71. Voron T, et al. VEGF A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212, 139-148 (2015).
72. Akalay I, et al. EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. Autophagy. 9, 1104-1106 (2013).
73. Demotte N, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity. 28, 414-424 (2008).
74. Motz G. T, & Coukos G. Deciphering, and reversing tumor immune suppression. Immunity. 39, 61-73 (2013).
75. Biswas S. K, & Mantovani A. Macrophage plasticity, and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889-896 (2010).
76. Mosser D. M, & Edwards J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958-969 (2008).
77. De Vos van Steenwijk P. J, et al. Tumor-infiltrating CD14 positive myeloid cells, and CD8 positive T cells prolong survival in patients with cervical carcinoma. Int. J. Cancer. 133, 2884-2894 (2013).
78. Ma J, et al. The M1 form of tumor-Associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 10, 112 (2010).
79. Heys S. D, et al. Characterisation of tumour-infiltrating macrophages: impact on response, and survival in patients receiving primary chemotherapy for breast cancer. Breast Cancer Res. Treat. 135, 539-548 (2012).
80. Ohri C. M, Shikotra A, Green R. H, Waller D. A, & Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur. Respir. J. 33, 118-126 (2009).
81. Heusinkveld M, et al. M2 macrophages induced by prostaglandin E2, and IL 6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 187, 1157-1165 (2011).
82. Lewis C. E, & Pollard J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612 (2006).
83. Coward J, et al. Interleukin 6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083-6096 (2011).
84. Wouters M. C. A, et al. Interleukin 6 receptor, and its ligand interleukin 6 are opposite markers for survival, and infiltration with mature myeloid cells in ovarian cancer. Oncoimmunology 3, e962397 (2015).
85. Predina J, et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc. Natl Acad. Sci. USA 110, E415-E424 (2013).
86. Mantovani A, & Allavena P. The interaction of anticancer therapies with tumor-Associated macrophages. J. Exp. Med. 212, 435-445 (2015).
87. van der Sluis T. C, et al. Therapeutic peptide vaccine-induced CD8 T cells strongly modulate intratumoral macrophages required for tumor regression. Cancer Immunol. Res. 3, 1042-1051 (2015).
88. Hagemann T, et al. Re educating tumor-Associated macrophages by targeting NF kappaB. J. Exp. Med. 205, 1261-1268 (2008).
89. Van den Boorn J. G, & Hartmann G. Turning tumors into vaccines: co opting the innate immune system. Immunity. 39, 27-37 (2013).
90. Dijkgraaf E. M, et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 73, 2480-2492 (2013).
91. Dijkgraaf E. M, et al. A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti IL 6R monoclonal antibody, and interferon α2b in patients with recurrent epithelial ovarian cancer. Ann. Oncol. 26, 2141-2149 (2015).
92. Panni R. Z, Linehan D. C, & DeNardo D. G. Targeting tumor-infiltrating macrophages to combat cancer. Immunotherapy. 5, 1075-1087 (2013).
93. Arina A, & Bronte V. Myeloid-derived suppressor cell impact on endogenous, and adoptively transferred T cells. Curr. Opin. Immunol. 33, 120-125 (2015).
94. Marigo I, et al. Tumor-induced tolerance, and immune suppression depend on the C/EBPβ transcription factor. Immunity. 32, 790-802 (2010).
95. Arina A, et al. Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression. J. Immunol. 192, 1286-1293 (2014).
96. Walter S, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254-1261 (2012).
97. Meyer C, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247-257 (2014).
98. Kimura T, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev. Res. (Phila) 6, 18-26 (2013).
99. Antonia S. J, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12, 878-887 (2006).
100. Bronte V, et al. Identification of a CD11b+/Gr 1+/.CD31+ myeloid progenitor capable of activating or suppressing CD8+ T cells. Blood. 96, 3838-3846 (2000).
101. Kerkar S. P, et al. IL 12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746-4757 (2011).
102. Steding C. E, et al. The role of interleukin 12 on modulating myeloid-derived suppressor cells, increasing overall survival, and reducing metastasis. Immunology. 133, 221-238 (2011).
103. Bonertz A, et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119, 3311-3321 (2009).
104. Van der Burg S. H, et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl Acad. Sci. USA. 104, 12087-12092 (2007).
105. Piersma S. J, Welters M. J, & van der Burg S. H. Tumor-specific regulatory T cells in cancer patients. Hum. Immunol. 69, 241-249 (2008).
106. Welters M. J, et al. Success or failure of vaccination for HPV16 positive vulvar lesions correlates with kinetics, and phenotype of induced T cell responses. Proc. Natl Acad. Sci. USA. 107, 11895-11899 (2010).
107. Zhou G, Drake C. G, & Levitsky H. I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 107, 628-636 (2006).
108. De Vries I. J, et al. Immunomonitoring tumor-specific T cells in delayed-Type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J. Clin. Oncol. 23, 5779-5787 (2005).
109. Rech A. J, et al. CD25 blockade depletes, and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci. Transl Med. 4, 134ra62 (2012).
110. Huss D. J, et al. In vivo maintenance of human regulatory T cells during CD25 blockade. J. Immunol. 194, 84-92 (2015).
111. Colombo M. P, & Piconese S. Regulatory-T cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer. 7, 880-887 (2007).
112. Alizadeh D, & Larmonier N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res. 74, 2663-2668 (2014).
113. Mitchell D. A, et al. Tetanus toxoid, and CCL3 improve dendritic cell vaccines in mice, and glioblastoma patients. Nature. 519, 366-369 (2015).
114. Van Hall T, & van der Burg S. H. Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity. Adv. Immunol. 114, 51-76 (2012).
115. Arens R, van Hall T, van der Burg S. H, Ossendorp F, & Melief C. J. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin. Immunol. 25, 182-190 (2013).
116. Klebanoff C. A, Gattinoni L, & Restifo N. P. CD8+ T cell memory in tumor immunology, and immunotherapy. Immunol. Rev. 211, 214-224 (2006).
117. Klebanoff C. A, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA. 102, 9571-9576 (2005).
118. De Vos van Steenwijk P. J, et al. The long-Term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Cancer Immunol. Immunother. 63, 147-160 (2014).
119. Karbach J, et al. Efficient in vivo priming by vaccination with recombinant NY ESO 1 protein, and CpG in antigen naive prostate cancer patients. Clin. Cancer Res. 17, 861-870 (2011).
120. Stebbing J, et al. An intra-patient placebo-controlled phase I trial to evaluate the safety, and tolerability of intradermal IMM 101 in melanoma. Ann. Oncol. 23, 1314-1319 (2012).
121. Rittig S. M, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+, and CD4+ immune responses, and induce clinical benefit in vaccinated patients. Mol. Ther. 19, 990-999 (2011).
122. Sampson J. H, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722-4729 (2010).
123. Van den Hende M, et al. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects, and patients with cervical neoplasia. Int. J. Cancer. 123, 146-152 (2008).
124. Coffman R. L, Sher A, & Seder R. A. Vaccine adjuvants: putting innate immunity to work. Immunity. 33, 492-503 (2010).
125. Schuurhuis D. H, et al. Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J. Exp. Med. 192, 145-150 (2000).
126. Mellman I, & Steinman R. M. Dendritic cells: specialized, and regulated antigen processing machines. Cell. 106, 255-258 (2001).
127. Gay N. J, & Gangloff M. Structure, and function of Toll receptors, and their ligands. Annu. Rev. Biochem. 76, 141-165 (2007).
128. Zwaveling S, et al. Established human papillomavirus type 16 expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169, 350-358 (2002).
129. Welters M. J, et al. Multiple CD4, and CD8 T cell activation parameters predict vaccine efficacy in vivo mediated by individual DC activating agonists. Vaccine. 25, 1379-1389 (2007).
130. Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD 1 blockade. Sci. Transl Med. 7, 283ra52 (2015).
131. Burdette D. L, & Vance R. E. STING, and the innate immune response to nucleic acids in the cytosol. Nat. Immunol. 14, 19-26 (2013).
132. Zom G. G, Khan S, Filippov D. V, & Ossendorp F. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv. Immunol. 114, 177-201 (2012).
133. Wen Y, & Collier J. H. Supramolecular peptide vaccines: tuning adaptive immunity. Curr. Opin. Immunol. 35, 73-79 (2015).
134. Khan S, et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282, 21145-21159 (2007).
135. Van der Burg S. H, Bijker M. S, Welters M. J, Offringa R, & Melief C. J. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Adv. Drug Deliv. Rev. 58, 916-930 (2006).
136. Daftarian P, et al. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity, and HIV recognition. Vaccine. 23, 3453-3468 (2005).
137. Zhang H, et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+, and CD4+ T cells. J. Biol. Chem. 284, 9184-9191 (2009).
138. Vecchi S, et al. Conjugation of a TLR7 agonist, and antigen enhances protection in the S. pneumoniae murine infection model. Eur. J. Pharm. Biopharm. 87, 310-317 (2014).
139. Zom G. G, et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol. Res. 2, 756-764 (2014).
140. Deres K, Schild H, Wiesmuller K. H, Jung G, & Rammensee H. G. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 342, 561-564 (1989).
141. Van Montfoort N, et al. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc. Natl Acad. Sci. USA. 106, 6730-6735 (2009).
142. Willems M. M, et al. N tetradecylcarbamyl lipopeptides as novel agonists for Toll-like receptor 2. J. Med. Chem. 57, 6873-6878 (2014).
143. Brahmer J. R, et al. Safety, and activity of anti PD L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465 (2012).
144. Topalian S. L, et al. Safety, activity, and immune correlates of anti PD 1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
145. Royal R. E, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA 4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828-833 (2010).
146. Gooden M, et al. HLA E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes. Proc. Natl Acad. Sci. USA. 108, 10656-10661 (2011).
147. Tumeh P. C, et al. PD 1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515, 568-571 (2014).
148. Piersma S. J, et al. Human papilloma virus specific T cells infiltrating cervical cancer, and draining lymph nodes show remarkably frequent use of HLA DQ, and -DP as a restriction element. Int. J. Cancer. 122, 486-494 (2008).
149. De Vos van Steenwijk P. J, et al. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 70, 2707-2717 (2010).
150. Koch M, et al. Tumor infiltrating T lymphocytes in colorectal cancer: tumor-selective activation, and cytotoxic activity in situ. Ann. Surg. 244, 986-992 (2006).
151. Fridman W. H, Pages F, Sautes-Fridman C, & Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer. 12, 298-306 (2012).
152. Mellman I, Coukos G, & Dranoff G. Cancer immunotherapy comes of age. Nature. 480, 480-489 (2011).
153. Van Elsas A, et al. Elucidating the autoimmune, and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen 4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis, and therapy. J. Exp. Med. 194, 481-489 (2001).
154. Duraiswamy J, Kaluza K. M, Freeman G. J, & Coukos G. Dual blockade of PD 1, and CTLA 4 combined with tumor vaccine effectively restores T cell rejection function in tumors. Cancer Res. 73, 3591-3603 (2013).
155. Van den Eertwegh A. J, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-Transduced allogeneic prostate cancer cells, and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13, 509-517 (2012).
156. Le D. T, & Jaffee E. M. Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J. Natl Compr. Canc. Netw. 11, 766-772 (2013).
157. Melero I, et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer. 15, 457-472 (2015).
158. Boissonnas A, Fetler L, Zeelenberg I. S, Hugues S, & Amigorena S. In vivo imaging of cytotoxic T cell infiltration, and elimination of a solid tumor. J. Exp. Med. 204, 345-356 (2007).
159. Bos R, & Sherman L. A. CD4+ T cell help in the tumor milieu is required for recruitment, and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70, 8368-8377 (2010).
160. Agarwal P, et al. Gene regulation, and chromatin remodeling by IL 12, and type I IFN in programming for CD8 T cell effector function, and memory. J. Immunol. 183, 1695-1704 (2009).
161. Spranger S, et al. Up regulation of PD L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl Med. 5, 200ra116 (2013).
162. Fourcade J, et al. PD 1, and Tim 3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccines. Cancer Res. 74, 1045-1055 (2014).
163. Soares K. C, et al. PD 1/PD L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors. J. Immunother. 38, 1-11 (2015).
164. Church S. E, Jensen S. M, Antony P. A, Restifo N. P, & Fox B. A. Tumor-specific CD4+ T cells maintain effector, and memory tumor-specific CD8+ T cells. Eur. J. Immunol. 44, 69-79 (2014).
165. Hanahan D, & Weinberg R. A. The hallmarks of cancer. Cell. 100, 57-70 (2000).
166. Zitvogel L, Galluzzi L, Smyth M. J, & Kroemer G. Mechanism of action of conventional, and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 39, 74-88 (2013).
167. Kang T. H, et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res. 73, 2493-2504 (2013).
168. Ramakrishnan R, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 120, 1111-1124 (2010).
169. Bae S. H, et al. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-Treated tumors to CTL-mediated killing in therapeutic synergy. Clin. Cancer Res. 13, 341-349 (2007).
170. Tseng C. W, et al. Pretreatment with cisplatin enhances E7 specific CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Clin. Cancer Res. 14, 3185-3192 (2008).
171. Sin J. I, et al. Adoptive transfer of human papillomavirus E7 specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol. Ther. 17, 906-913 (2009).
172. Van der Most R. G, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS ONE 4, e6982 (2009).
173. Huang X, Huang G, Song H, & Chen L. Preconditioning chemotherapy with paclitaxel, and cisplatin enhances the antitumor activity of cytokine induced-killer cells in a murine lung carcinoma model. Int. J. Cancer. 129, 648-658 (2011).
174. Nowak A. K, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-Tolerizing host tumor-specific CD8 T cells. J. Immunol. 170, 4905-4913 (2003).
175. Tang C, et al. Combining radiation, and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol. Res. 2, 831-838 (2014).
176. Kleinovink J. W, et al. Combination of photodynamic therapy, and specific immunotherapy efficiently eradicates established tumors. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-15-0515 (2015).
177. Peng S, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol. Immunother. 62, 171-182 (2013).
178. Ghiringhelli F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells, and restores T, and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56, 641-648 (2007).
179. Vermeij R, et al. Potentiation of a p53 SLP vaccine by cyclophosphamide in ovarian cancer: a single-Arm phase II study. Int. J. Cancer 131, E670-E680 (2012).
180. Rettig L, et al. Gemcitabine depletes regulatory T cells in human, and mice, and enhances triggering of vaccine-specific cytotoxic T cells. Int. J. Cancer. 129, 832-838 (2011).
181. Dijkgraaf E. M, et al. A Phase 1/2 study combining gemcitabine, Pegintron, and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget. 6, 32228-32243 (2015).
182. Srivastava M. K, Sinha P, Clements V. K, Rodriguez P, & Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T cell activation by depleting cystine, and cysteine. Cancer Res. 70, 68-77 (2010).
183. Suzuki E, Kapoor V, Jassar A. S, Kaiser L. R, & Albelda S. M. Gemcitabine selectively eliminates splenic Gr 1+/CD11b+ myeloid suppressor cells in tumor-bearing animals, and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721 (2005).
184. Beatty G. L, et al. CD40 agonists alter tumor stroma, and show efficacy against pancreatic carcinoma in mice, and humans. Science. 331, 1612-1616 (2011).
185. Kodumudi K. N, et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583-4594 (2010).
186. Vincent J, et al. 5 Fluorouracil selectively kills tumor-Associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010).
187. Sevko A, et al. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells, and chronic inflammation in the spontaneous melanoma model. J. Immunol. 190, 2464-2471 (2013).
188. Van der Sluis T. C, et al. Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death. Clin. Cancer Res. 21, 781-794 (2015).
189. Sato Y, et al. Immunological evaluation of personalized peptide vaccination in combination with a 5 fluorouracil derivative (TS 1) for advanced gastric or colorectal carcinoma patients. Cancer Sci. 98, 1113-1119 (2007).
190. Arlen P. M, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12, 1260-1269 (2006).
191. Masuzawa T, et al. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1, and 2 in patients with advanced gastric cancer. Int. J. Oncol. 41, 1297-1304 (2012).
192. Suzuki N, et al. A phase I clinical trial of vaccination with KIF20A derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J. Immunother. 37, 36-42 (2014).
193. Nishida S, et al. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J. Immunother. 37, 105-114 (2014).
194. Geller M. A, Bui-Nguyen T. M, Rogers L. M, & Ramakrishnan S. Chemotherapy induces macrophage chemoattractant protein 1 production in ovarian cancer. Int. J. Gynecol. Cancer. 20, 918-925 (2010).
195. Qian D. Z, et al. CCL2 is induced by chemotherapy, and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate. 70, 433-442 (2010).
196. Emens L. A, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety, and immune activation. J. Clin. Oncol. 27, 5911-5918 (2009).
197. Nistico P, et al. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int. J. Cancer. 124, 130-139 (2009).
198. Palermo B, et al. Dacarbazine treatment before peptide vaccination enlarges T cell repertoire diversity of melan A specific, tumor-reactive CTL in melanoma patients. Cancer Res. 70, 7084-7092 (2010).
199. Van Poelgeest M. I, et al. HPV16 synthetic long peptide (HPV16 SLP) vaccination therapy of patients with advanced or recurrent HPV16 induced gynecological carcinoma, a phase II trial. J. Transl Med. 11, 88 (2013).
200. Welters M. J, et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci. Transl Med. (in the press).
201. US National Library of Medicine. ClinicalTrials.gov, https://clinicaltrials.gov/ct2/show/NCT02128126 (2016).
202. Rosenberg S. A, & Restifo N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 348, 62-68 (2015).
203. Kohlmeyer J, et al. Complete regression of advanced primary, and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 69, 6265-6274 (2009).
204. Pilon-Thomas S, Mackay A, Vohra N, & Mule J. J. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J. Immunol. 184, 3442-3449 (2010).
205. Ly L. V, et al. Peptide vaccination after T cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. Cancer Res. 70, 8339-8346 (2010).
206. Verdegaal E. M, et al. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+, and CD8+ T cells in combination with low-dose interferon-α. Cancer Immunol. Immunother. 60, 953-963 (2011).
207. Lattanzi L, et al. IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology. 216, 537-547 (2011).
208. Singh S. K, et al. The simultaneous ex vivo detection of low-frequency antigen-specific CD4+, and CD8+ T cell responses using overlapping peptide pools. Cancer Immunol. Immunother. 61, 1953-1963 (2012).
209. Zeestraten E. C, et al. Addition of interferon-α to the p53 SLP(R) vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int. J. Cancer. 132, 1581-1591 (2013).
210. Rapoport A. P, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE A3/.poly-ICLC immunizations followed by adoptive transfer of vaccine-primed, and costimulated autologous T cells. Clin. Cancer Res. 20, 1355-1365 (2014).
211. Nelson B. H. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185, 4977-4982 (2010).
212. Germain C, Gnjatic S, & Dieu-Nosjean M. C. Tertiary lymphoid structure-Associated B cells are key players in anti-Tumor immunity. Front. Immunol. 6, 67 (2015).
213. Kenter G. G, et al. Vaccination against HPV 16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
214. Van Poelgeest M. I, et al. Therapeutic vaccination with or without imiquimod as adjuvant for vulvar/vaginal intraepithelial neoplasia: an open-label randomised controlled phase 1/2 trial. Clin. Cancer Res. http://.dx.doi.org/10.1158/1078-0432.CCR-15-2594 (2015).
215. Daayana S, et al. Phase II trial of imiquimod, and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br. J. Cancer. 102, 1129-1136 (2010).
216. Trimble C. L, et al. Safety, efficacy, and immunogenicity of VGX 3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16, and 18 E6, and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 386, 2078-2088 (2015).
217. Czerniecki B. J, et al. Targeting HER 2/neu in early breast cancer development using dendritic cells with staged interleukin 12 burst secretion. Cancer Res. 67, 1842-1852 (2007).
218. Romero I, Garrido F, & Garcia-Lora A. M. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer. Cancer Res. 74, 6750-6757 (2014).
219. Koebel C. M, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 903-907 (2007).
220. Manley C. A, et al. Xenogeneic murine tyrosinase DNA vaccine for malignant melanoma of the digit of dogs. J. Vet. Intern. Med. 25, 94-99 (2011).
221. Morse M. A, et al. A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA, and MUC1 compared with the same poxvectors plus GM CSF for resected metastatic colorectal cancer. Ann. Surg. 258, 879-886 (2013).
222. Ibrahim N. K, et al. Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl Tn-KLH vaccine: post hoc analysis of a large randomized trial. J. Cancer. 4, 577-584 (2013).
223. Holmes J. P, et al. Optimal dose, and schedule of an HER 2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01, and I-02. Cancer. 113, 1666-1675 (2008).
224. Mittendorf E. A, et al. Clinical trial results of the HER 2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01, and I-02. Cancer. 118, 2594-2602 (2012).
225. Landsberg J, et al. Melanomas resist T cell therapy through inflammation-induced reversible dedifferentiation. Nature. 490, 412-416 (2012).
226. Schlecker E, et al. Metalloprotease-mediated Tumor Cell Shedding of B7 H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30. Cancer Res. 74, 3429-3440 (2014).
227. Medema J. P, de Jong J, van Hall T, Melief C. J, & Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE- inhibitory protein. J. Exp. Med. 190, 1033-1038 (1999).
228. Munn D. H, & Mellor A. L. Indoleamine 2,3 dioxygenase, and metabolic control of immune responses. Trends Immunol. 34, 137-143 (2013).
229. Hildner K, et al. Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity. Science. 322, 1097-1100 (2008).
230. Fuertes M. B, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208, 2005-2016 (2011).
231. Pozzi L. A, Maciaszek J. W, & Rock K. L. Both dendritic cells, and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J. Immunol. 175, 2071-2081 (2005).
232. Lyman M. A, et al. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J. Immunol. 174, 2563-2572 (2005).
233. Wong S. B, Bos R, & Sherman L. A. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-Avidity CD8+ T cells. J. Immunol. 180, 3122-3131 (2008).
234. Driessens G, Kline J, & Gajewski T. F. Costimulatory, and coinhibitory receptors in anti-Tumor immunity. Immunol. Rev. 229, 126-144 (2009).
235. Schwartz R. H. T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
236. Croft M, Benedict C. A, & Ware C. F. Clinical targeting of the TNF, and TNFR superfamilies. Nat. Rev. Drug Discov. 12, 147-268 (2013).
237. Dong H, et al. Tumor-Associated B7 H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800 (2002).
238. Parry R. V, et al. CTLA 4, and PD 1 receptors inhibit T cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543-9553 (2005).
239. Blackburn S. D, et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
240. Curtsinger J. M, Gerner M. Y, Lins D. C, & Mescher M. F. Signal 3 availability limits the CD8 T cell response to a solid tumor. J. Immunol. 178, 6752-6760 (2007).
241. Sikora A. G, et al. IFN-Alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J. Immunol. 182, 7398-7407 (2009).
242. Boyman O, & Sprent J. The role of interleukin 2 during homeostasis, and activation of the immune system. Nat. Rev. Immunol. 12, 180-190 (2012).
243. Redeker A, et al. The quantity of autocrine IL 2 governs the expansion potential of CD8+ T cells. J. Immunol. 195, 4792-4801 (2015).
244. Dunn G. P, Bruce A. T, Ikeda H, Old L. J, & Schreiber R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).